SOURCE: OmniComm Systems, Inc.

OmniComm Systems, Inc.

September 22, 2015 08:00 ET

OmniComm Systems® Signs 5-Year, Multi-Million Dollar TrialMaster® EDC Agreement with Major CRO

This Deal Highlights a Strong H1 2015 With Net Revenue Growth of 42% YOY

FORT LAUDERDALE, FL--(Marketwired - September 22, 2015) - OmniComm Systems, Inc. (OmniComm) (OTCQX: OMCM), a global leading provider of clinical data management technology, today announced a five year, multi-million dollar agreement with a leading contract research organization (CRO) for OmniComm’s TrialMaster electronic data capture technology (EDC).

Ranked within the top 5 CROs for excellence in clinical monitoring and clinical research, this CRO selected TrialMaster to meet their current and future data management requirements for their expanding number of Phase I through Phase IV clinical studies.

TrialMaster was selected for its inherent flexibility, scalability and broad capabilities to support clinical studies across all phases of clinical development. The latest release of TrialMaster includes over 300 new innovative productivity and functionality enhancements. Deploying studies in an efficient, timely and cost effective manner was especially important to the CRO as well as the speed of knowledge transfer for self-reliance. OmniComm’s dedication to EDC product development, as well as our robust, state-of-the art compliant hosting environment was critical in their selection process.

“Today, our specialized EDC technologies offer unique features that help CROs deliver far greater benefits to their clients in terms of better business insight, quality, timeliness and cost,” said Kuno van der Post, SVP of business development, OmniComm. “Our CRO partners are now using these strengths to successfully differentiate themselves in the sales cycle against those other CROs offering older, weakly developed and less functionally rich systems.”

“We are pleased with the addition of yet another leading CRO to our client list. This deal highlights another great first half for us -- one in which we’ve seen 42% year-over-year growth in our revenue compared to the first half of 2014,” stated Stephen Johnson, president and COO of OmniComm Systems. “We are focused not only on growing revenue but also controlling operating and overhead expenses for the remainder of FY 2015.”

Supporting Information

  • OmniComm Systems Announces Innovative New Release of TrialMaster® EDC
  • TrialMaster

About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,000 clinical trials. For more information, visit www.omnicomm.com.

Trademarks
OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.